StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a report released on Thursday.
A number of other equities analysts have also weighed in on ABUS. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 target price (up from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.50.
Check Out Our Latest Analysis on ABUS
Arbutus Biopharma Trading Down 0.6 %
Hedge Funds Weigh In On Arbutus Biopharma
A number of large investors have recently modified their holdings of ABUS. Intech Investment Management LLC acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $142,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Arbutus Biopharma by 218.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after buying an additional 831,663 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Arbutus Biopharma by 453.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 30,723 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $754,000. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $243,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Recommended Stories
- Five stocks we like better than Arbutus Biopharma
- There Are Different Types of Stock To Invest In
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 REITs to Buy and Hold for the Long Term
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to start investing in penny stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.